Acute Monoblastic and Monocytic Leukemia
Associated Genetic Biomarkers
NCI Definition: Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features. 
Acute monoblastic and monocytic leukemias most frequently harbor alterations in TET2, FLT3, DNMT3A, NPM1, and IDH2 .
FLT3 Mutation, DNMT3A Mutation, NPM1fs, IDH2 Mutation, and IDH2 Exon 4 Mutation are the most common alterations in acute monoblastic and monocytic leukemia .
There is 1 clinical trial for acute monoblastic and monocytic leukemia, of which 1 is open and 0 are completed or closed. Of the trial that contains acute monoblastic and monocytic leukemia as an inclusion criterion, 1 is phase 1 (1 open).
BCR-ABL1, PML-RARA, and t(15;17)(q22;q12) are the most frequent gene inclusion criteria for acute monoblastic and monocytic leukemia clinical trials .
Io-202 is the most common intervention in acute monoblastic and monocytic leukemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.